Lipotoxicity and Impaired High Density Lipoprotein-Mediated Reverse Cholesterol Transport in Chronic Kidney Disease

被引:83
|
作者
Vaziri, Nosratola D. [1 ,2 ]
机构
[1] Univ Calif Irvine, Dept Med, Div Nephrol & Hypertens, Irvine, CA 92717 USA
[2] Univ Calif Irvine, Div Nephrol & Hypertens, Dept Physiol & Biophys, Irvine, CA 92717 USA
关键词
APOLIPOPROTEIN-A-I; STAGE RENAL-DISEASE; TYPE-2; DIABETES-MELLITUS; ESTER TRANSFER PROTEIN; DOWN-REGULATION; OXIDATIVE STRESS; CARDIOVASCULAR EVENTS; LIPASE EXPRESSION; VASCULAR-DISEASE; HEPATIC LIPASE;
D O I
10.1053/j.jrn.2010.05.010
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Chronic kidney disease (CKD) is associated with a high risk of death from cardiovascular disease. Inflammation, oxidative stress, and dyslipidemia, which are common consequences of CKD, contribute to the pathogenesis of atherosclerosis and cardiovascular disease in this population. Dyslipidemia of CKD is characterized by diminished plasma high density lipoprotein (HDL) concentration, impaired HDL anti-oxidant and anti-inflammatory activities, and elevated plasma triglyceride, very low density lipoprotein (VLDL), intermediate density lipoprotein, chylomicron remnants, and oxidized lipids and lipoproteins. The constellation of inflammation, HDL deficiency, and oxidative modification of lipoproteins can cause atherosclerosis and progression of renal disease. We have recently found lipid accumulation in the remnant kidney and the wall of aorta in rats with CKD induced by 5/6 nephrectomy. This was mediated by up-regulation of scavenger receptors involved in the influx of oxidized lipids or lipoproteins, tubular reabsorption of lipid binding proteins through megalin-cubilin complexes, upregulation of fatty acid synthesis, and downregulation of fatty acid oxidation pathways. The combination of increased lipid influx, elevated production and reduced catabolism of lipids, and impaired HDL-mediated reverse cholesterol transport can promote atherosclerosis, glomerulosclerosis, and tubulointerstitial damage. Although statins can be effective in slowing CKD progression in patients with mild-to-moderate CKD, they have consistently failed to mitigate oxidative stress, inflammation, HDL deficiency, or cardiovascular mortality in the end-stage renal disease populations. Similarly, high doses of antioxidant vitamins have failed to either ameliorate oxidative stress, inflammation, or improve overall mortality in end-stage renal disease. This article is intended to provide a brief review of the effects of CKD on HDL structure and function and pathways of lipid influx, efflux, synthesis, and catabolism in the artery wall and the diseased kidney. (C) 2010 by the National Kidney Foundation, Inc. All rights reserved.
引用
收藏
页码:S35 / S43
页数:9
相关论文
共 50 条
  • [21] Familial massive tendon xanthomatosis with decreased high-density lipoprotein-mediated cholesterol efflux
    Matsuura, F
    Hirano, K
    Koseki, M
    Ohama, T
    Matsuyama, A
    Tsujii, K
    Komuro, R
    Nishida, M
    Sakai, N
    Hiraoka, H
    Nakamura, T
    Yamashita, S
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2005, 54 (08): : 1095 - 1101
  • [22] PROBUCOL, HIGH-DENSITY LIPOPROTEIN METABOLISM AND REVERSE CHOLESTEROL TRANSPORT
    GWYNNE, JT
    AMERICAN JOURNAL OF CARDIOLOGY, 1988, 62 (03): : B48 - B51
  • [23] High-Density Lipoprotein Function, Dysfunction, and Reverse Cholesterol Transport
    Fisher, Edward A.
    Feig, Jonathan E.
    Hewing, Bernd
    Hazen, Stanley L.
    Smith, Jonathan D.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2012, 32 (12) : 2813 - 2820
  • [24] High-density lipoprotein heterogeneity and function in reverse cholesterol transport
    Rothblat, George H.
    Phillips, Michael C.
    CURRENT OPINION IN LIPIDOLOGY, 2010, 21 (03) : 229 - 238
  • [26] High-density lipoprotein-mediated cardioprotection in heart failure
    Ampadu O. Jackson
    Jun Meng
    Huifang Tang
    Kai Yin
    Heart Failure Reviews, 2021, 26 : 767 - 780
  • [27] High density lipoprotein cholesterol levels are an independent predictor of the progression of chronic kidney disease
    Baragetti, A.
    Norata, G. D.
    Sarcina, C.
    Rastelli, F.
    Grigore, L.
    Garlaschelli, K.
    Uboldi, P.
    Baragetti, I.
    Pozzi, C.
    Catapano, A. L.
    JOURNAL OF INTERNAL MEDICINE, 2013, 274 (03) : 252 - 262
  • [28] Role of Hepatic Lipase and Endothelial Lipase in High-Density Lipoprotein—Mediated Reverse Cholesterol Transport
    Wijtske Annema
    Uwe J. F. Tietge
    Current Atherosclerosis Reports, 2011, 13 : 257 - 265
  • [29] Role of Phospholipid Transfer Protein in High-Density Lipoprotein- Mediated Reverse Cholesterol Transport
    Yazdanyar, Amirfarbod
    Yeang, Calvin
    Jiang, Xian-Cheng
    CURRENT ATHEROSCLEROSIS REPORTS, 2011, 13 (03) : 242 - 248
  • [30] RAISING HIGH-DENSITY-LIPOPROTEIN CHOLESTEROL - THE BIOCHEMICAL PHARMACOLOGY OF REVERSE CHOLESTEROL TRANSPORT
    MILLER, NE
    BIOCHEMICAL PHARMACOLOGY, 1990, 40 (03) : 403 - 410